The pact also allows both the parties to get access to SAFE-BioPharma interoperable digital identity credentials which is a form of software installed on a computer, cell phone or other device which establishes a close link with the user’s proven identity and allows for the application of legally binding, digital signatures to electronic documents.
SAFE-BioPharma Association president and CEO Mollie Shields-Uehling said Forest Laboratories and the Allergy Asthma Research Institute are streamlining their systems by shifting to interoperable digital identities and digital signatures.